|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||28.24 - 28.74|
|52 Week Range||28.24 - 36.82|
|PE Ratio (TTM)||21.42|
|Forward Dividend & Yield||1.11 (3.93%)|
|1y Target Est||N/A|
AbbVie's key lung cancer candidate, Rova-T falls short in a phase II study, J&J gets buyout offer for its LifeScan unit from private firm, Platinum Equity.
A dozen drugs launching in 2018 from heavy-hitters like Roche, Gilead and J&J are expected to hit blockbuster status over the next five years, an analytics firm predicted Thursday.
Novartis' (NVS) Tasigna and Seattle Genetics' (SGEN) Adcetris receive regulatory approvals for label expansion. Pfizer's label expansion application for Xtandi gets priority review.
Roche's (RHHBY) opthalmology drug, Lucentis 0.3 mg prefilled syringe (PFS) is a new method of administering medicine for all forms of diabetic retinopathy.
On March 7, 2018, Teva Pharmaceutical (TEVA) with Teva Canada and Xenon Pharmaceuticals (XENE) entered into a mutual agreement to terminate the collaborative development and license agreement they entered into in 2012 for the pain drug TV-45070. During Xenon Pharmaceuticals’ 2017 earnings results release, it announced the agreement termination news. On the day, TEVA stock rose ~0.8%, while Xenon stock rose ~7%. Teva Pharmaceutical stated that it was no longer interested in the development of TV-45070.
Cut-price copies of an expensive Roche (ROG.S) biotech drug for blood cancer have taken 80 percent of the British market since launching last year, saving the healthcare system 80 million pounds a year, experts said on Wednesday. The rapid adoption of two so-called biosimilar forms of rituximab from Celltrion and Novartis (NOVN.S) has been accompanied by discounts of 50-60 percent as the National Health Service (NHS) has used tenders to bring down costs. The situation contrasts sharply with the United States, where regulators have lagged Europe in approving biosimilars while a complex system of rebates offered to insurers by original-brand drugmakers has created barriers to use.
Cut-price copies of an expensive Roche biotech drug for blood cancer have taken 80 percent of the British market since launching last year, saving the healthcare system 80 million pounds ($113 million) a year, experts said on Wednesday. The rapid adoption of two so-called biosimilar forms of rituximab from Celltrion and Novartis has been accompanied by discounts of 50-60 percent as the National Health Service (NHS) has used tenders to bring down costs. The situation contrasts sharply with the United States, where regulators have lagged Europe in approving biosimilars while a complex system of rebates offered to insurers by original-brand drugmakers has created barriers to use.
Shares of Prothena (PRTA) surged significantly after the company announced a multi-year collaboration with leading company Celgene to develop new therapies for a broad range of neurodegenerative diseases.
Roche (RHHBY) announces that the combination study of Tecentriq plus chemotherapy meets its co-primary endpoint of progression-free survival.
Roche's immunotherapy Tecentriq on Tuesday racked up a third trial win in combination with other cancer drugs, a boost for the Swiss drugmaker as it seeks to muscle in on space dominated by Merck and Bristol-Myers Squibb. A late-stage study, called IMpower131, demonstrated Tecentriq mixed with chemotherapies carboplatin and Abraxane cut risk of disease worsening or death (PFS), compared with chemotherapy alone, in first-line treatment of patients with advanced squamous non-small cell lung cancer.
Roche's (ROG.S) immunotherapy Tecentriq plus chemotherapy cut the risk of disease worsening or death in advanced squamous lung cancer, but it did not yet show an overall survival benefit in this tough-to-treat disease, the Swiss drugmaker said Tuesday. A late-stage study, called IMpower131, demonstrated that Tecentriq combined with carboplatin and Abraxane boosted progression-free survival (PFS), compared with chemotherapy alone, in patients getting initial treatment.
Prothena (PRTA) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Immune Design (IMDZ) reports narrower-than-expected loss in fourth quarter 2017 results and updates data for its pipeline candidates.
Inovio (INO) reports a narrower-than-expected loss in Q4. Moreover, revenues also beat estimates during the period and increased year over year.
In 4Q17, Merck’s (MRK) Emend generated revenues of $143 million, which reflected a ~1% decline on a YoY (year-over-year) basis but a 4% rise on a QoQ (quarter-over-quarter) basis. In 4Q17, in the US and in international markets, Emend reported revenues of $85 million and $58 million, respectively, compared with $90 million and $53 million in 4Q16, which reflected a ~6% decline and an 8% rise, respectively, YoY. In fiscal 2017, Emend generated revenues of $556 million, compared with $549 million in 2016, which reflected a ~1% rise YoY.
In 2017, Novo Nordisk’s (NVO) Saxenda sales reached 2.6 billion Danish kroner, a YoY (year-over-year) rise of 64% in local currencies. According to IQVIA, by the end of November 2017, Saxenda accounted for 79%, 86%, 72%, 52%, 47%, 40%, 30%, 19%, 14%, and 6% of the total value of anti-obesity medications sold in the United Arab Emirates, Canada, Denmark, the United States, Italy, Spain, Brazil, Germany, Australia, and Mexico, respectively. In December 2017, Novo Nordisk submitted an application to the FDA seeking an update to Saxenda’s label to include data from the LEADER trial.
Swiss drugmaker Roche (ROG.S) said it will put a cancer specialist at the helm of its Swiss-based research efforts in April, after the scientist who led the unit for five years resigned for personal reasons. The biggest maker of cancer drugs named William Pao to lead its 2,200-employee Pharma Research and Early Development (pRED) unit on Thursday. Current postholder Reed, 59, arrived in Basel in 2013 to rebuild Roche's Swiss research after restructuring.
The chief U.S. economist at Standard & Poor’s says reductions in workplace gender inequalities could actually help the economy grow by 5-10% over the next few decades. Yahoo Finance’s Alexis Christoforous, Dan Roberts and Julia La Roche discuss.